English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

THE C3H/HeJ strain of mice obtained from the Jackson Laboratory (Bar Harbor, Maine, U.S.A.) shows a high incidence of spontaneous mammary cancer (Green, 1966). Bacillus Calmette Guerin (BCG) is an effective immunopotentiator and has been used as an adjuvant to control neoplastic growth in both experimental animals and humans. In all probability, it exerts this action by enhancing the macrophage response to foreign antigen (Hersh, Gutterman and Mavleget, 1977). A multitude of papers reviewed by Bardawil and Troy (1959) attests to the various effects produced in experimental animals by immunization with heterologous antisera to placental homogenates. The use of placental tissue alone for immunization has also been examined (Jones, Ing and Kaye, 1972). The effect of a combined vaccine containing autogenous placenta and BCG on the incidence of autochthonous mammary cancer in a highly susceptible animal has not hitherto been adequately investigated and is the subject of this study. Tumour cells possess at least 2 antigens at the cell surface which elicit cellular immune reaction: foetal antigen and tumour-specific transplantation antigen (TSTA). The current belief is that these 2 antigens may not be distinct entities but are both the expression of normal cellular components present during normal embryonic development (Coggen and Anderson, 1972). Accepted 24 October 1977

A vaccine containing autogenous term placenta and an immunopoteniator to reduce the incidence of autochthonous cancer